Navigation Links
Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

/li>

Design of RESILIENCE: A phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer.

  • Jose Baselga, M.D., Ph.D., Massachusetts General Hospital
  • Abstract number: TPS123
  • June 6, 8:00 am – 12:00 pm, Trials in Progress Poster Session

Development and validation of a prediction tool for hand-foot skin reaction (HFSR) in patients receiving sorafenib

  • Jian Yu, M.D., University of Pittsburgh Cancer Institute
  • Abstract number: 2605
  • June 6, 8:00 am – 12:00 pm, General Poster Session

In addition, data from the Bayer and Onyx-sponsored Phase IV prospective study, GIDEON, which was accepted for Best of ASCO® 2011, will be presented:

GIDEON (Global investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] And Of Its Treatment with Sorafenib) 2nd interim analysis in more than 1500 Patients: clinical findings in patients with liver dysfunction

  • Jorge Marrero, M.D., Associate Professor, Department of Internal Medicine, University of Michigan
  • Abstract number: 4001
  • June 7, 9:45 am, Oral abstract session

"There is a variety of abstracts evaluating the utility of sorafenib being presented at this year's ASCO," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "We look forward to continuing additional research in order to understand how sorafenib may fit into other therapeutic areas and tumor types."

About Nexavar

Nexavar is approved in the U.S. for the treatment of patients with unresectable liver cancer and for the treatment of patients with advanced kidney cancer. Nexavar inhibits both the
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
2. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
3. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
4. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
5. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
6. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
7. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
8. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
11. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... -- Big Cloud Analytics, Inc. (BCA), a leading provider ... working with Intel Corporation to showcase Internet of ... Healthcare Technology Alliance. The recently formed alliance is ... technology companies and academic institutions. Its purpose is ... in rapidly evolving and growing areas of health ...
(Date:7/30/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ) ... Canaccord Genuity 35th Annual Growth Conference on Wednesday, August ... Boston Hotel.  A webcast of the ... are encouraged to visit the web site at least ... to register, download and install any necessary software.  The ...
Breaking Medicine Technology:Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... RenovoCath,™ a novel catheter that was developed for targeted delivery of fluids to ... now being treated at Florida Hospital Tampa with the device that provides direct, ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Awarded to only ... is proud to announce that they are the latest recipients of the Center ... status as one of the worldwide leaders in the science of hair transplant. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a multidisciplinary ... website at Healthpointe.net. The new website will feature a sleek and streamlined design ... to provide smoother interactions between patients and the Healthpointe clinics and ensures that ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
(Date:7/31/2015)... MI (PRWEB) , ... July 31, 2015 , ... ... Essential Oils are 100% organic, natural, therapeutic-grade oils from ingredients sourced all over ... Eilers, explains that “With considerable effort, we have developed the highest-quality oils in ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... , , , ... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported financial results for ... $209.4 million for the quarter ended June 30, 2009, which includes net ... million associated with the Company,s sales force reduction in the second quarter, ...
... Wednesday, August 5, 2009, ... 9:00 a.m. EDT, ... 1-800-731-5774, ... to participate in a briefing on Wednesday, August 5, with David B. Holtz, Interim President Chief Executive ...
... , MEQUON, Wis., July 21 Wonderbox ... its clients to benefit from continued advances in technology and ... Management Module designed for managed care benefit administration and case ... tools for scheduling, managing, and monitoring day-to-day care tasks and ...
... American men could be putting their health at risk ... results might threaten their masculinity. Because they prove their ... advice including HIV/AIDS testing goes against their notion of ... Department of Sociology at Yale University in the US, ...
... Mich., July 21 The Michigan Chamber of Commerce ... health care reform and urged Michigan,s Congressional Delegation to demand ... , , "Like the U.S. ... and the President to reform the health care system for ...
... , , OWINGS MILLS, Md., ... leading portion-controlled weight-loss program, today announced the launch of Honey Mustard ... and Parmesan Cheese Puffs. The new pretzel sticks and cheese puffs ... & 1 Plan, while also maintaining the nutritional value of Medifast ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 12Health News:Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results 2Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2Health News:'Go to the doctor? Only if I'm really sick ...' 2Health News:Michigan Chamber of Commerce Raises Concerns With Flawed Federal Health Care Reform Proposal, Rushed Timeline 2Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 2Health News:Medifast Adds Pretzel and Puffs to Meal Replacement Line 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: